FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552274424> ?p ?o ?g. }

• W2552274424 abstract "Abstract Background: The efficacy of epoetin beta (E) is well documented in clinical trials in anemic cancer patients (pts). This study was conducted to assess E use, efficacy, safety and effect on quality of life in cancer pts, in usual practice. Methods: This prospective, multicenter, longitudinal, observational French study assessed a 4-month follow-up of informed consent cancer pts (including both solid tumors (ST) and non-myeloid hematological malignancies (H)) treated with E for chemotherapy-related anemia. Data were collected between January 2005 and March 2006. We only present here the results of the H subgroup. Results: Among 2809 pts, 675 had an H including 325 non-Hodgkin lymphoma (NHL), 181 multiple myeloma (MM) and 80 chronic lymphocytic leukemia (CLL). 52% of pts received their first line of chemotherapy, 24% their second one. At inclusion, Hb levels were distributed as follows: &lt; 9 g/dl: 32%, [9–11[ g/dl, 56%, [11–13[ g/dl, 11%. At inclusion, endogenous erythropoietin rate was monitored for only 8% of pts, ferritin was available for 32%, transferrin saturation for 17% and reticulocytes for 24%. At initiation, pts received a median dose of 30000 U/week of E on a once weekly regimen schedule for 98% of pts. E was associated with iron supplementation in 20% of pts (1% IV). The mean Hb level increased from 10 g/dl [5 – 14] at baseline to 13 g/dl [7 – 17] in the entire cohort of H pts, from 10 g/dl [5 – 14] to 12 g/dl [7 – 16] in NHL pts, from 10 g/dl [6 – 13] to 13 g/dl [8 – 17] in MM pts and from 10 g/dl [6 – 13] to 13 g/dl [7 – 17] in CLL pts. Hb response rate (RR) was 56% (CI95: 51 – 61) in H pts, 53% (CI95: 46 – 60) in NHL pts, 57% (CI95: 48 – 66) in MM pts and 56% (CI95: 41 – 70) in CLL pts. 41% of patients were transfused at inclusion or during the study. Good performance status (PS≤1) (OR=1.6, CI95: 1.1–2.5), non platinum-based regimen (OR=2.4, CI95: 1.2–4.9) and iron supplementation (OR=2.6, CI95: 1.4–5.1) are identified both in univariate and multivariate analysis as predictive factors of Hb response. The mean of FACT score improved from 29 (CI95: 26–31) at initiation to 36 (CI95: 34–38) at the end of study (p&lt;0.0001). Thromboembolic events were reported in 2% of patients. Conclusion: These results confirm the efficacy and safety of epoetin beta in routine practice for anemic patients with a non-myeloid hematological malignancy receiving chemotherapy. Epoetin beta improves the quality of life measured by FACT score." @default.
• W2552274424 created "2016-11-30" @default.
• W2552274424 creator A5004333812 @default.
• W2552274424 creator A5014517118 @default.
• W2552274424 creator A5024260899 @default.
• W2552274424 creator A5025996482 @default.
• W2552274424 creator A5031041032 @default.
• W2552274424 creator A5037324033 @default.
• W2552274424 creator A5041108107 @default.
• W2552274424 creator A5041419953 @default.
• W2552274424 creator A5061613197 @default.
• W2552274424 creator A5071589084 @default.
• W2552274424 date "2007-11-16" @default.
• W2552274424 modified "2023-10-01" @default.
• W2552274424 title "Epoetin Beta (Neorecormon®) Treatment for Anemia of Patients with Non-Myeloid Hematological Malignancy under Chemotherapy: Results of a Large Prospective Cohort Study." @default.
• W2552274424 doi "https://doi.org/10.1182/blood.v110.11.3777.3777" @default.
• W2552274424 hasPublicationYear "2007" @default.
• W2552274424 type Work @default.
• W2552274424 sameAs 2552274424 @default.
• W2552274424 citedByCount "0" @default.
• W2552274424 crossrefType "journal-article" @default.
• W2552274424 hasAuthorship W2552274424A5004333812 @default.
• W2552274424 hasAuthorship W2552274424A5014517118 @default.
• W2552274424 hasAuthorship W2552274424A5024260899 @default.
• W2552274424 hasAuthorship W2552274424A5025996482 @default.
• W2552274424 hasAuthorship W2552274424A5031041032 @default.
• W2552274424 hasAuthorship W2552274424A5037324033 @default.
• W2552274424 hasAuthorship W2552274424A5041108107 @default.
• W2552274424 hasAuthorship W2552274424A5041419953 @default.
• W2552274424 hasAuthorship W2552274424A5061613197 @default.
• W2552274424 hasAuthorship W2552274424A5071589084 @default.
• W2552274424 hasConcept C126322002 @default.
• W2552274424 hasConcept C141071460 @default.
• W2552274424 hasConcept C2776694085 @default.
• W2552274424 hasConcept C2778248108 @default.
• W2552274424 hasConcept C2778319317 @default.
• W2552274424 hasConcept C2778336483 @default.
• W2552274424 hasConcept C2781413609 @default.
• W2552274424 hasConcept C71924100 @default.
• W2552274424 hasConcept C90924648 @default.
• W2552274424 hasConceptScore W2552274424C126322002 @default.
• W2552274424 hasConceptScore W2552274424C141071460 @default.
• W2552274424 hasConceptScore W2552274424C2776694085 @default.
• W2552274424 hasConceptScore W2552274424C2778248108 @default.
• W2552274424 hasConceptScore W2552274424C2778319317 @default.
• W2552274424 hasConceptScore W2552274424C2778336483 @default.
• W2552274424 hasConceptScore W2552274424C2781413609 @default.
• W2552274424 hasConceptScore W2552274424C71924100 @default.
• W2552274424 hasConceptScore W2552274424C90924648 @default.
• W2552274424 hasLocation W25522744241 @default.
• W2552274424 hasOpenAccess W2552274424 @default.
• W2552274424 hasPrimaryLocation W25522744241 @default.
• W2552274424 hasRelatedWork W123411078 @default.
• W2552274424 hasRelatedWork W1968837563 @default.
• W2552274424 hasRelatedWork W1970829184 @default.
• W2552274424 hasRelatedWork W2347614275 @default.
• W2552274424 hasRelatedWork W2384740383 @default.
• W2552274424 hasRelatedWork W2557278076 @default.
• W2552274424 hasRelatedWork W2918056756 @default.
• W2552274424 hasRelatedWork W3047389906 @default.
• W2552274424 hasRelatedWork W3136440833 @default.
• W2552274424 hasRelatedWork W1540236315 @default.
• W2552274424 isParatext "false" @default.
• W2552274424 isRetracted "false" @default.
• W2552274424 magId "2552274424" @default.
• W2552274424 workType "article" @default.